Sintilimab-IFN alpha fusion protein - Innovent Biologics
Alternative Names: PD1-IFN alpha fusion protein - Innovent BiologicsLatest Information Update: 31 May 2025
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Immunotherapies; Interferons; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interferon alpha replacements; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours